RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xynomic, a clinical stage Delaware-Shanghai pharma, has filed three China INDs for its lead candidate, abexinostat, a novel HDAC inhibitor. The potentially pivotal trials will test abexinostat, a China Category 1 drug, against renal cell carcinoma and lymphoma. Abexinostat is already in a global Phase III trial, paired with pazopanib, as a first- or second-line therapy for metastatic renal cell carcinoma. Xynonic is an in-licensing company that is developing drugs for China and the US.
Source: China Biotoday
